science behind semaglutide 💉⚖️ — The Modern Weight Loss Therapy A major shift in obesity treatment is here. Semaglutide is transforming how we understand weight loss — from willpower to biology. 🧠 Weekend Reads | The Science

The FLOW trial The FLOW trial, published in the New England Journal of Medicine in 2024, tested subcutaneous semaglutide 1.0 mg (the Ozempic dose, not the higher Wegovy dose) in 3,533 people with type 2 diabetes and CKD

When you inject Wegovy, you can trust that each 0.25 mg dose contains exactly 0.25 mg of active semaglutide base

The worst-case scenario is not treating obesity at all and experiencing progressive metabolic deterioration, cardiovascular disease, diabetes, and reduced quality of life over decades

The standard dose is 37.5 mg once daily, taken in the morning before breakfast or 1 to 2 hours after breakfast